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Abstract
Background
Allergic non-asthmatic (ANA) adults experience upper airway symptoms of allergic disease
such as rhinorrhea, congestion and sneezing without symptoms of asthma. The aim of this
study was to utilize PET-CT functional imaging to determine whether allergen challenge
elicits a pulmonary response in ANA subjects or whether their allergic disease is truly iso-
lated to the upper airways.
Methods
In 6 ANA subjects, bronchoalveolar lavages (BAL) were performed at baseline and 24h
after instillation of an allergen and a diluent in separate lung lobes. After instillation (10h),
functional imaging was performed to quantify and compare regional perfusion, ventilation,
fractional gas content (Fgas), and glucose uptake rate (Ki) between the baseline, diluent
and allergen lobes. BAL cell counts were also compared.
Results
In ANA subjects, compared to the baseline and diluent lobes, perfusion and ventilation were
significantly lower in the allergen lobe (median [inter-quartile range], baseline vs. diluent vs.
allergen: Mean-normalized perfusion; 0.87 [0.85–0.97] vs. 0.90 [0.86–0.98] vs. 0.59 [0.55–
0.67]; p<0.05. Mean-normalized ventilation 0.89 [0.88–0.98] vs. 0.95 [0.89–1.02] vs. 0.63
[0.52–0.67], p<0.05). In contrast, no significant differences were found in Fgas between
baseline, diluent and allergen lobes or in Ki. Total cell counts, eosinophil and neutrophil cell
counts (cells/ml BAL) were significantly greater in the allergen lobe compared to the base-
line lobe (all P<0.05).
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Conclusions
Despite having no clinical symptoms of a lower airway allergic response (cough and
wheeze) allergic non-asthmatic subjects have a pulmonary response to allergen exposure
which manifests as reduced ventilation and perfusion.
Introduction
Allergen exposure in allergic non-asthmatic (ANA) adults causes upper airway symptoms such
as sneezing, rhinorrhea and nasal and/or sinus congestion. In contrast, allergen exposure in
allergic asthmatic (AA) subjects causes lower airway narrowing and pulmonary symptoms of
wheeze and cough which may occur in concert with upper airway symptoms [1]. Despite dif-
ferences in symptoms, both AA and ANA subjects have been shown to have similar lower air-
way cellular inflammatory responses to allergen challenge [2,3]. It remains unclear why similar
cellular inflammatory responses invoke disparate clinical symptoms in AA and ANA subjects,
and if allergen challenge in ANA subjects leads to alterations in regional lung function as has
been shown during broncoconstriction in asthma [4,5]. One possibility is that allergen expo-
sure in ANA subjects does not impact regional lung function.
Using functional PET-CT imaging in AA subjects, we have previously shown that segmental
allergen challenge causes an allergic inflammatory cellular response in addition to regional
physiological changes in the allergen exposed lobe compared to the control lobes [6]. Specifi-
cally, regional reductions in perfusion, ventilation, lung aeration and elevated glucose metabo-
lism occurred in the allergen exposed lobe compared to the control lobes [6]. These findings
suggest that the allergic inflammatory response in the lower airways of AA subjects results in
clearly identifiable physiological changes that may account for the pulmonary symptoms in
these subjects. Given that ANA subjects, following allergen exposure, exhibit symptoms of an
upper airway allergic response without pulmonary symptoms, it is reasonable that they may
not experience the reductions in perfusion, ventilation, lung aeration and elevated glucose
metabolism that occur in AA subjects. However, whether the lower airway cellular inflamma-
tory response in ANA subjects following allergen challenge manifests as alterations in regional
physiologic function such as ventilation and perfusion remains unknown.
Our aim was to use PET-CT functional imaging (13NN-saline and 18F-Fluorodeoxyglucose,
18F-FDG) to determine whether, in ANA subjects, segmental allergen challenge causes regional
reductions in perfusion, ventilation, lung aeration and elevated glucose uptake. We hypothe-
sized that ANA subjects would elicit a cellular inflammatory response to segmental challenge
but have no regional physiologic responses.
Materials and Methods
Study Protocol
The Institutional Review Board of the Massachusetts General Hospital approved the study and
all six subjects (4 female) provided written informed consent (Protocol No. 2008-P000408).
Subjects were not taking any medications other than loratadine for control of allergy symp-
toms, which was withheld for 12 h prior to the first bronchoscopy. The study consisted of a
screening visit, two hospital visits and a bronchoscopy-imaging visit.
Allergic Non-Asthmatic Pulmonary Response
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Study Inclusion Criteria
Study inclusion criteria required a clinical history of allergic symptoms to cat or house dust
mite with demonstrated positive skin prick test reactivity, age 18–50 years, no history of
asthma and a documented lack of airways hyperresponsiveness (methacholine PC20> 16 mg/
ml). The PC20 describes the concentration of methacholine required to provoke a 20%
decrease in FEV1 [7]. Caution was taken to exclude subjects who were asthmatic, including
those who did not present with asthmatic symptoms. The initial phone screen investigated sub-
jects’ respiratory history through a series of questions pertaining to past breathing difficulties.
During the screening visit, subjects needed to demonstrate a normal baseline spirometry (FEV1
and FVC both>90% predicted). During the second visit, subjects needed to demonstrate a
negative methacholine bronchial challenge test (PC20> 16 mg/ml.) Subjects with allergic rhi-
nitis were studied outside of symptomatic pollen seasons. Exclusion criteria also included sub-
jects with a BMI> 35 kg/m2, pregnant (confirmed via a positive serum pregnancy test) or
nursing women, subjects with previous radiation exposure in research studies within the previ-
ous 12 months, and subjects with any concomitant lung disease or co-morbidities such as dia-
betes or known cardiac disease. Subjects had to be non-smokers for the previous 5 years with
a< 10 pack year smoking history, have no evidence of respiratory tract infection in the previ-
ous 6 weeks or antibiotic use for respiratory complaints within the month prior to the first
bronchoscopy visit, no history of exposure to asbestos or silica, and no anti-histamine use in
the 7 days prior to the screening. Subjects who were unable to lay flat for more than 2 hours,
had previous immunotherapy with cat or house dust mite extract, and subjects with known
allergy or hypersensitivity to 18F-FDG were also excluded.
Screening Visit
The screening visit included a full medical history, baseline spirometry (Morgan Heated FVL,
Haverhill, MA USA) and serum pregnancy testing. Allergen skin testing was performed to first
establish atopy to cat dander or house dust mite and was followed by quantitative allergen skin
prick testing using serial 3-fold dilutions of either cat dander (Cat) or house dust mite Derma-
tophagoides Pterynissinus (DP) allergen to establish the minimum allergen concentration
required to elicit an inflammatory response (3 mm wheal diameter) [8], which was the concen-
tration subsequently instilled during the segmental lobe challenge. All allergens were purchased
from Greer Laboratories (Lenoir, NC USA).
Bronchoscopy-Imaging Visit
The bronchoscopy-imaging visit included two bronchoscopies separated by 24 h and PET-CT
imaging with 18F-FDG and 13NN-saline approximately ~10 h after the first bronchoscopy. The
timing of the bronchoscopies, 24 hours apart, was specifically selected to capture the peak in
the T-cell response [9,10]. It was not possible to perform the bronchoscopes and imaging at the
same time due to constraints in the scheduling of bronchoscopies and PET-CT imaging. As a
result, the closest possible time the imaging could be completed with respect to the bronchos-
copies was 10 hours after the first bronchoscopy, which corresponds to ~12 hours prior to the
second bronchoscopy.
The segmental allergen bronchoscopy methods were based on those developed by Lilly et.
al. [8]. Each fiberoptic bronchoscopy was performed under conscious sedation with topical
anesthesia (< 300 mg lidocane, total dose). During the first bronchoscopy a bronchial-alveolar
lavage (BAL) was performed in the lingula/left upper lobe (LUL, Fig 1) with 120 mL of saline.
The allergen (Cat or DP) was instilled (2 mL) in either the medial or lateral segment of the
Right Middle Lobe (RML, Fig 1) at a concentration determined from quantitative skin prick
Allergic Non-Asthmatic Pulmonary Response
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testing. Also, due to the presence of a small amount of endotoxin within the instilled allergen
solutions, 2ml of the respective diluent, which also contains the endotoxin (0.9% sodium chlo-
ride, 0.03% albumin and 0.4% phenol), was instilled in the anterior segment of the right upper
lobe (RUL, Fig 1). The second bronchoscopy included a BAL performed on both the RUL and
RML, each of 120 ml. The amount of endotoxin within the instilled cat allergen extract ranged
from 5.0–6.5 endotoxin units/ml and for the DP allergen the range was 1.5–81 endotoxin
units/ml. Endotoxin was measured in the undiluted commercial allergen extracts by kinetic
turbidimetric chromogenic testing (Charles River Laboratories, Inc. Charleston SC). Please
note, following the conclusion of this study, our group has since altered our segmental allergen
technique to further reduce the risk of systemic allergic reaction. Specifically, the instilled DP
allergen dose was reduced to 1/3 of the skin prick test threshold concentration as a result of
hives developing in a subject in a parallel study.
Image Instrumentation, Acquisition and Reconstruction
Prior to any imaging, subjects were instrumented with impedance plethysmography bands to
monitor thoracic gas volume (SomnoStar PT, SensorMedics, Loma Linda, CA) and a periph-
eral intravenous catheter was inserted to allow for serum pregnancy test, delivery of the radio-
active tracers and blood sampling during 18F-FDG imaging.
All images were obtained on a Biograph 64 PET-CT scanner (Siemans, Malvern, PA USA).
Following instrumentation, a High-Resolution Computed Tomograph (HRCT) of the thorax
was obtained (Xray tube current 160 mA, 120kVp) at Mean Lung Volume (MLV). MLV was
defined as the average lung volume during relaxed tidal breathing in the supine position and
was determined via impedance plethysmography for the 30 sec of breathing just prior to image
acquisition. The HRCT scan was reconstructed using a B31 kernel yielding an in-plane image
resolution of 0.9766×0.9766 mm, in-plane image size of 512×512 voxels, slice thickness of 0.75
mm and a beam pitch of 0.5 mm. The HRCT image was used for quantification of lung aera-
tion, for the reconstruction of both the 13NN and 18F-FDG PET scans to correct for attenuation
due to body tissues and for image segmentation (Apollo Workstation, Vida Diagnostics, Coral-
ville, IA USA). Image segmentation yielded mask images of the lung and lobes.
A 13NN-Saline emission scan was performed following the HRCT scan. Specifically, at the
onset of a 20–30 sec breath-hold at MLV, a bolus of 13NN-Saline was injected intravenously
Fig 1. Lung image demonstrating the location of the different lung lobes. The left upper lobe (LUL) was
used as the baseline (blue), the right upper lobe (RUL) was used as the diluent lobe (red) and the right middle
lobe (RML) was the allergen exposed lobe (green).
doi:10.1371/journal.pone.0143976.g001
Allergic Non-Asthmatic Pulmonary Response
PLOS ONE | DOI:10.1371/journal.pone.0143976 December 7, 2015 4 / 13
(11.2 [9.5–11.7] mCi). At the conclusion of the breath-hold, the subject was instructed to
resume breathing for 3 min 10 s at the same frequency and tidal volume as recorded prior to
the apnea (visual feedback provided via video goggles) while imaging of the 13NN washout for
3 min 10 s (total image time 3 min 40 s). The 13NN-saline emission scan allows for the assess-
ment of regional pulmonary perfusion (Q) and specific ventilation (sV). The theoretical basis
of this emission scan is the low solubility of nitrogen in tissues (partition coefficient λwater/air,
0.0015 at 37◦C), whereby on arrival of the 13NN-saline bolus into the pulmonary capillaries
virtually all the tracer diffuses into the alveolar space on first-pass. Therefore the accumulation
of 13NN in the alveolar space during the breath-hold period can be used as a measure of relative
Q. With the resumption of breathing, the tracer is removed via ventilation and therefore the
rate of removal of 13NN can be used to estimate regional sV.
13NN-saline PET scans were reconstructed using filtered back projection yielding dynamic
scans with a voxel size of 5.3456×5.3456×2.025 mm, 128×128×81 voxels per frame and 16
frames (frame duration: 8×5 s, 3×10 s, 5×30 s). PET scans were filtered using a 3 dimensional
moving average filter resulting in an effective image resolution of 10.125 mm.
Gas fraction (Fgas) was computed for each voxel by converting the HRCT density, Houns-
field units (HU) to Fgas, where Fgas = (densityblood−densityvoxel)/ (densityblood−densityair),
using densityblood = 65 and densityair = −1000.
The 18F-FDG PET scans were commenced following the intravenous infusion of 18F-FDG
(10.1 [9.6–10.3] mCi). From the onset of the infusion, each dynamic PET scan was acquired
for a total of 52 min 45 s duration. In order to calibrate the FDG image, venous blood samples
were acquired during the FDG image at set time points, 5 min 30 s, 9 min 30 s, 25 min, 37 min
and 42 min 30 s, as described previously [11]. The blood samples (~1 ml) were centrifuged and
the activity in the isolated plasma assessed with a gamma counter. FDG imaging is based on
FDG uptake by cells via the same mechanism as glucose but subsequent trapping within the
cell as 18F-FDG-6-phosphate following phosphorylation by hexokinase results in accumulation
within the cell in proportion to the cells’ metabolic rate allowing for the determination of the
18F-FDG net uptake rate (see Image Analysis below). 18F-FDG scans were reconstructed using
filtered back projection with the same geometry as the 13NN-saline scans but with 36 frames
(frame duration: 9×10 s, 3×15 s, 1×30s, 7×60s, 14×120, 1×300 s, 1×600 s).
Image analysis
For all image analysis, the exposed lung lobe, instead of the exposed lung segment, was used to
assess the influence of the allergen and the diluent and to establish a baseline condition. The
use of lung lobes significantly reduces the potential error in lung segmentation.
Ventilation and Perfusion: Voxel by voxel specific ventilation (sV) and perfusion (Q) were
computed from dynamic PET scans of 13NN-Saline kinetics as previously described [12] and
were then used to determine the regional mean normalized sV and Q in the baseline, diluent
and allergen lobes.
Lung Aeration: Using the HRCT, the mean regional lung aeration was computed in the
baseline, diluent and allergen lobes as the average gas fraction (Fgas; gas volume/total volume)
relative the mean Fgas of the whole lung.
Cellular Metabolic Rate: Cellular metabolic activity in the baseline, diluent and allergen
lobes were measured as the net 18F-FDG uptake rate (Ki), calculated via the Patlak method
[13,14]. Specifically, both the lung activity and the integral of the plasma activity were normal-
ized to the plasma activity and then plotted against each other. When the transfer of tracer
between the plasma and the intercellular compartments reached a plateau, the plot of normal-
ized lung activity vs. the integral of plasma activity linearizes (~ 8–10 min after 18F-FDG
Allergic Non-Asthmatic Pulmonary Response
PLOS ONE | DOI:10.1371/journal.pone.0143976 December 7, 2015 5 / 13
administration). The slope of this linear portion of the curve was estimated using linear regres-
sion and reflects the 18F-FDG uptake rate (Ki).
Cellular analysis
Cellular analysis was completed on each BAL sample as previously described [6]. Total cell
counts per ml of collected BAL were computed along with differential cell counts per ml of col-
lected BAL for eosinophils, neutrophils and mononuclear leukocytes.
Statistical Analysis
Non-parametric statistics were used and reported as median [interquartile range], unless other-
wise stated. Specifically, inter-subject differences in the allergen, diluent and baseline means of
Q, sV, Fgas and cell counts were completed with analysis of variance on Ranks and Tukey pair-
wise tests (allergen vs. diluent, allergen vs. baseline, diluent vs. baseline). Statistical analysis was
completed using SigmaPlot (Systat Software, San Jose, CA USA) and Matlab (Mathworks,
Natick MA, USA). Statistical significance was accepted at P<0.05. No corrections were made
for multiple comparisons.
Results
Subject characteristics, allergen dosing and lung function, including percentage predicted val-
ues [15] are included in Table 1. All subjects had normal lung function with no evidence of air-
flow obstruction. To enable individual subjects to be tracked throughout the figures, each
subject is identified by a unique marker, subject 1 circle, subject 2 square, subject 3 diamond,
subject 4 triangle, subject 5 upside down triangle, subject 6 hexagon.
PET-CT functional outcomes
Both the relative Q and sV were significantly lower in the allergen lobe compared to the diluent
lobe (P<0.05) and baseline lobes (P<0.05 Fig 2). No differences in Fgas were found between
the baseline, diluent or allergen lobes (Fig 2). For one subject the baseline lobe 18F-FDG analy-
sis was unable to be completed due to a local edge effect as a result of patient movement and
was therefore excluded from the statistical analysis. Comparison of the 18F-FDG uptake rate
(Ki) in the baseline, diluent and allergen lobes (Fig 2) found no significant difference in the Ki
between the baseline, diluent and allergen lobes.
Typical regional distributions of Fgas, Q, sV, and Ki in the allergen and diluent lobe in three
subjects are shown in Fig 3. Note that the Fgas images show distinct regional alterations in lung
aeration in two subjects and no changes in the third subject. Also, perfusion and ventilation
images demonstrate substantial differences in the allergen lobe in all three subjects shown, par-
ticularly noticeable at the lobe boundary. Finally, the allergen lobe shows higher relative Ki in
two subjects but a weaker response is seen in the third subject.
Cellular outcomes
Comparisons of cell counts (per ml of returned bronchoalveolar lavage fluid) between condi-
tions (baseline, diluent and allergen) are included in Fig 4. The allergen BAL had significantly
higher total cell counts/ml, eosinophil counts/ml and neutrophil counts/ml compared to the
baseline BAL (P<0.05) as determined by cytospins. No differences were found between the
baseline, diluent and allergen BAL for mononuclear leukocytes. Furthermore, no significant
differences in cell counts between the baseline and diluent or between diluent and allergen
Allergic Non-Asthmatic Pulmonary Response
PLOS ONE | DOI:10.1371/journal.pone.0143976 December 7, 2015 6 / 13
Table 1. Subject demographics, lung function and allergen dosing.
Subject Gender Age,
yrs
Height, cm BMI, kg/
m2
FEV1, L (%
pred.)
FVC, L (%pred.) FEV1/FVC PC20,
mg/mL
Allergen Dose #
1 F 20 160.0 22.1 4.03 (126) 4.37 (123) 0.92 19.96 DP 370
2 M 28 185.4 25.1 4.76 (98) 5.76 (99) 0.83 20.64 DP 1111
3 F 33 165.1 28.5 3.64 (120) 4.51 (126) 0.81 >25 DP 41
4 M 49 180.3 34.7 3.42 (85) 4.31 (87) 0.79 >25 DP 370
5 F 24 177.8 21.5 3.65 (101) 4.49 (104) 0.81 >25 Cat 370
6 F 31 162.6 24.3 3.85 (128) 5.10 (145) 0.75 >25 DP 123
Median
[IQR]
M:F 2:4 30 [25–
33]
171.5
[163.2–
179.7]
24.7
[22.7–
27.6]
3.75 [3.64–3.99]
(111 [99–125])
4.50 [4.40–4.95]
(114 [100–125])
0.81
[0.80–
0.82]
- DP:Cat
5:1
370
[185–
370]
# Dose units are Bioequivalent Allergy Units (BAU)/ml for cat dander and Allergy Units (AU)/ml for the DP extract. Two mL of extract was instilled during
each segmental allergen challenge.
doi:10.1371/journal.pone.0143976.t001
Fig 2. Physiological changes in response to segmental allergen challenge. Both relative perfusion (A) and specific ventilation (B) were significantly
lower in the allergen lobe compared to the baseline and diluent lobes. (C) However, overall the fractional gas content was not different between the baseline,
diluent and allergen segments. (D) Ki uptake rate was also not different between the baseline, diluent and allergen segments.
doi:10.1371/journal.pone.0143976.g002
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lobes were found for any cell type. However, for the allergen lobe total cell counts and eosino-
phil cell counts were greater than the diluent counts in all subjects.
Discussion
In this study we found that allergic non-asthmatics can exhibit a regional pulmonary response
to segmental allergen challenge even though, clinically, they experience no pulmonary allergic
symptoms. Specifically, the allergen lobe was seen to have lower perfusion and ventilation com-
pared to the baseline and diluent lobes, a similar response to that seen in AA subjects following
segmental allergen challenge [6]. It follows that AA and ANA subjects are not easily distin-
guishable based on their regional physiological response to segmental allergen challenge. Given
that the cellular allergic inflammation was similar, it could be that the AA phenotype arises
from small chronic anatomic differences in the airways between AA and ANA resulting in a
Fig 3. Example images.Representative images of Fgas, Q, sV, and Ki in the diluent and allergen lobes from two subjects who had ground glass opacities
present on inspection of HRCT (Subject 1 and 4) and a separate subject with no ground glass opacities (Subject 6). Ground glass opacities are seen as
regions with increased red and black colors. In each image, the boundaries of the diluent and allergen lobes are outlined in blue. Note: Color scales differ
between subjects. Q, sV and Ki are represented as relative values, relative to the mean of the imaged lung.
doi:10.1371/journal.pone.0143976.g003
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lowering of the threshold for the airway tree to undergo “catastrophic” bronchoconstriction in
AA [5].
The lower ventilation found in the allergen lobe is likely the result of airway narrowing, par-
ticularly in the peripheral airways, which are frequently proposed as being responsible for
regional decreases in ventilation [16,17,18]. Peripheral airway narrowing and the associated
lower ventilation following segmental challenge could occur as a result of the regional cellular
allergic response as indicated by the greater concentrations of total cells, eosinophils and neu-
trophils (Fig 4). Increased concentrations of these inflammatory cells are associated with
increased microvascular leakage and/or cellular exudate production [19,20] and bronchocon-
striction, all of which could cause airway narrowing and therefore lower regional ventilation.
In the presence of reduced ventilation, perfusion may also be decreased [4] as low ventila-
tion leads to regional hypoxia, which in turn causes regional vascular constriction likely via
hypoxic pulmonary vasoconstriction [21,22]. The reduction of perfusion in regions with
reduced ventilation acts to preserve ventilation/perfusion matching and maintain gas
exchange, although some degree of mismatch still occurs [23]. Our current findings of lower
perfusion and ventilation in the allergen lobe in ANA and our similar findings in a previous
study of AA subjects [6], suggests that this effect may be a universal allergic response to seg-
mental allergen challenge in atopic subjects.
The lack of a difference in the degree of lung aeration between the baseline, diluent and
allergen lobes suggests that despite the degree of cellular infiltration in the allergen lobe being
Fig 4. Cellular changes in response to segmental allergen challenge.Comparison of cell counts per ml of BAL fluid in the baseline, diluent and allergen
BAL samples. The allergen BAL had significantly greater numbers of total cells, eosinophils, and neutrophils than the baseline BALs. No differences in the
mononuclear leukocyte cell counts were found between the baseline, diluent and allergen.
doi:10.1371/journal.pone.0143976.g004
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greater than baseline, this did not consistently lead to regional edema or atelectasis that was vis-
ible with HRCT imaging (2/6 subjects had distinct regional reductions in Fgas; Figs 2 and 3). In
contrast, lower lung aeration was found previously in the allergen lobe of AA subjects when
compared to the diluent and control lobes [6]. The lack of a reduction in lung aeration in the
ANA group may be the result of a lower degree of microvascular leakage and/or cellular exu-
date production in the ANA group following segmental challenge compared to the AA group.
However, despite any hypothetical differences in plasma exudation, AA and ANA subjects ulti-
mately experience similar degrees of lower ventilation. Additional, larger studies are warranted
to determine whether the degree of microvascular leakage and/or cellular exudation differs
between AA and ANA subjects and any role they play in altering lung aeration.
The degree of cellular infiltration following segmental challenge in the ANA subjects
reported here was similar to that reported previously in AA subjects. This finding is consistent
with the work of Shaver et. al. [24] and Becky Kelly et. al. [25], but this finding is not universal
[26,27]. It is possible that absolute cell populations may not be the dominant factor that distin-
guishes these two clinical phenotypes. Indeed other factors such as the cells capacity to release
mediators, their response to local stimulatory signals, or the response of structural cells in the
lung to the inflammatory cells may be more relevant. Subsequently, larger studies are required
to ascertain the importance of absolute cell populations vs. the functional/metabolic cellular
response in the clinical separation of AA and ANA subjects.
Study limitations
The main limitation of the current study is that the statistical power for differences among
parameters is limited as a result of the variability in responses and the small population studied.
One additional limitation of our current study is that the baseline, diluent and allergen lobes
were not randomized. Such randomization has not previously been included in segmental aller-
gen studies [6,8]. Therefore, systematic inter-lobar differences in perfusion, ventilation and lung
aeration may contribute to our findings in two ways. First, because the same volume of allergen/
diluent was instilled into lobes of differing size it may have affected the magnitude of the inflam-
matory responses. Specifically, the diluent lobe has, on average, 1.7 times greater total volume
than the allergen lobe, meaning that there is a greater potential for inflammatory cell release due
to the greater amount of lung tissue present in the diluent lobe compared to the allergen. Second,
the gravitational dependence of perfusion, ventilation and lung aeration is well reported [28,29]
and given that the RML is more non-dependent in the supine position than the RUL and LUL,
some of the differences in Fgas, perfusion and ventilation in the allergen lobe may be the result of
its location. However, the presence of consolidation and ground glass opacities within the RML
in a proportion of the ANA subjects (3 of 6; see Fig 2) is almost certainly the result of the instilla-
tion of the allergen and therefore it seems unlikely that the reduction in perfusion and ventilation
in the allergen lobe can be entirely explained by the specific lobe selected for the segmental chal-
lenge. Furthermore, when perfusion in the baseline, diluent and allergen lobes was plotted rela-
tive to the lung height (height frommost dependent part of the lung) the allergen lobe was seen
to have substantially lower perfusion than the control lobes for the same lung height in 3 subjects
(Fig 5). In the remaining 3 subjects, perfusion can be seen to deviate from the perfusion vs. height
trend for at least one lung height. Therefore, the location of the lobes with respect to gravity is
unlikely to account for the systematically lower perfusion in the allergen lobe.
Physiological Interpretation
Allergic non-asthmatic subjects, following allergen challenge, appear to experience the same
physiologic pulmonary disturbances as allergic asthmatic subjects. Therefore, it is not obvious
Allergic Non-Asthmatic Pulmonary Response
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from our findings how ANA subjects are ‘protected’ from lower airway symptoms that result
from their allergic disease. One potential explanation is that due to the complex network inter-
actions between airways and alveolar tissue [5], regional lung changes in ANA subjects are able
to be compensated by the remaining healthy lung and therefore pulmonary symptoms may not
manifest. Factors such as airway remodelling in AA subjects [30,31] may mean the normal
Fig 5. Perfusion relative to gravitational height.Mean normalized perfusion vs. lung height (from the most
dorsal point of the lung) in the baseline (grey-open circles), diluent (grey-filled circles) and allergen lobes
(black-filled circles) in all subjects (subjects identified by marker in top left of each panel). Each lobe is divided
into 8 equal volume regions along the gravitational axis and the mean perfusion and lung height of each
region plotted. The allergen lobe can be seen to have lower perfusion across several lung heights (grey
highlighted sections), compared to the diluent and allergen. In the remaining 3 subjects the allergen lobe can
be seen to deviate to the left of the perfusion height trend for at least one lung height (grey striped highlighted
sections). In the most dependent and most non–dependent heights the allergen lobe appears to have no
difference in perfusion compared to the baseline and diluent lobes at those equivalent lung heights.
doi:10.1371/journal.pone.0143976.g005
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compensatory mechanisms do not work and therefore AA subjects experience pulmonary
symptoms such as shortness of breath.
Conclusion
Despite having no clinical expression of airways disease, ANA subjects respond to segmental
allergen challenge with regional changes in perfusion, ventilation and cell counts that are simi-
lar to those that occur in AA subjects. It follows that the mechanisms which protect ANA sub-
jects from airways disease must differ from the parameters investigated herein. Additional
studies will be necessary to clarify if there is a quantitative difference in the magnitude of the
pulmonary response between asthmatic and non-asthmatic patients with allergies that may
explain the differences in the clinical manifestation of their allergic disease.
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